Free-text search
Content Types
-
Vitrolife appoints Elin Frostehav as new CEO
Elin Frostehav is leaving Getinge to take up the role of CEO at Vitrolife.
-
Lilly’s obesity ads on the underground cleared by watchdog
Eli Lilly’s advertising campaign about obesity did not breach industry rules on advertising aimed at the general public, according to a ruling by the Swedish ph...
-
Let's connect at COMPAMED 2026 in Düsseldorf
Gruber A/S will join the Danish Pavilion at COMPAMED in Düsseldorf on 16–19 November 2026, with a focus on manufacturing solutions for the medical and pharmaceu...
-
UK ends uncertainty over CE marking for medical devices
Medical device manufacturers will be spared duplicate certification processes to access the British market. The UK government has decided to recognise CE markin...
-
”Cybersecurity Is Patient Safety”
Avivit Kotler, Chief Information Security and Data Protection Officer at Clalit Health Services in Israel will participate in the MVA Annual Summit 2026 Novembe...
-
Spago plans stock market exit to facilitate fundraising
Swedish research company Spago Nanomedical plans to apply to delist from Nasdaq First North.
-
Pfizer job cuts reported at several manufacturing sites
Pfizer has previously announced a major cost-cutting programme. Now, reports have emerged of job losses at several of the pharmaceutical giant's manufacturing s...
-
Inossia raises SEK 88m – targets US approval
The Swedish medtech company Inossia, which is developing an additive for bone cement, has completed an oversubscribed SEK 88 million share issue.
-
Moderna plunged by double digits after study data leaked
Biotech company Moderna fell nearly 18 percent on the stock market after study data on the company’s mRNA-based cancer vaccine spread on social media ahead of t...
-
EQT leads €9.6bn buyout of Qiagen
Swedish investment firm EQT is poised to make a major acquisition in the diagnostics sector with a 9.6 billion euro bid for Dutch company Qiagen.
-
AstraZeneca wins new FDA approval for serious kidney disease
A new treatment indication has opened up for AstraZeneca’s Ultomiris following positive results from a phase III trial. The FDA has approved the drug for a rare...
-
Anna Rennermalm: Are we hiring the best candidate – or the best AI user?
When AI is used both to write and screen job applications, it is becoming increasingly difficult to assess what candidates can actually do. Could meeting in per...
-
Major spin-off: Abbott plans to separate nutrition business
Abbott's global nutrition business generates approximately $8.5 billion in annual sales. Now, the medtech giant has announced plans to spin off the business int...
-
AstraZeneca's labor ward drug withdrawal is due to lack of commercial viability
The upcoming withdrawal of labor drug Bricanyl is based on commercial calculations rather than supply chain problems.
-
Sciety appoints Thomas Eldered as senior advisor
Life science investment firm Sciety has appointed entrepreneur and business leader Thomas Eldered as its new senior advisor.
-
Swedish firm makes progress on antiviral treatment
A compound developed by Swedish company Virenc has shown promising results against SARS-CoV-2 in an advanced model of human airways. The findings mark a step fo...
-
New hair loss pill delivers positive Phase 3 results
A new tablet formulation of a drug originally developed to treat high blood pressure has shown promising results against hereditary hair loss.
-
GLP-1 drugs spark unexpected interest among perfume giants
The appetite-suppressing effects of weight-loss drugs are well known. But could they also change what people want to smell like? That question has now caught th...
-
Integrated Clinical and Regulatory Support for Oncology Trials
Aurevia is a European Contract Research Organization (CRO) and regulatory partner supporting biotech, pharmaceutical, and medtech companies in the development a...
-
Explore the ZEISS Innovation Summit 2026
The event serves a global platform where diverse perspectives come together, ideas are challenged, solutions take shape, and collaborations turn into action.
-
Roche doubles down on Chinese biotech in deal worth up to $15 billion
A year after their first antibody-drug conjugate deal, Roche and China’s Hansoh Pharmaceutical are expanding their partnership. The new agreement covers several...
-
Saniona moves depression drug closer to first-in-human trial
The Swedish-Danish research company Saniona has submitted an application to the FDA to begin testing its oral drug candidate in patients with major depressive disorder.
-
Merck KGAA to acquire Silence Therapeutics for billions
German pharmaceutical and chemical group Merck KGAA has entered into an agreement to acquire British biotechnology company Silence Therapeutics for approximatel...
-
Former Novo Nordisk CEO nominated as Lundbeck chair
Lars Fruergaard Jørgensen, former CEO of Novo Nordisk, has been nominated to become the new Chair of the Board at Lundbeck. He is expected to succeed Dorothea W...
BREAKING